This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-28. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
=== 2005 === 22 January Wave that Shook the World, an Equinox Special about the 2004 Indian Ocean earthquake and tsunami, preceded by a Dispatches Live Special on the same topic; the earthquake occurs in the Sunda Trench in Sumatra, the edge of the Sunda Plate for around four minutes; British geologist Bill McGuire (volcanologist) of UCL; engineering seismologist Thomas H. Heaton of Caltech; the earthquake had the strength of all the Earth's earthquakes in the previous five years; Barry Hirshorn of the Pacific Tsunami Warning Center; Simon Boxall of the National Oceanography Centre, Southampton; photographer Geoff Mackley; three-quarter of the deaths were in Sumatra; the 2004 Sri Lanka tsunami train wreck; Richard Gross of NASA's Airborne Science Program at JPL; the Cascadia subduction zone; the O. H. Hinsdale Wave Research Laboratory at Oregon State University. Produced by Martin Williams, directed by Lara Acaster, made by Pioneer Productions with Nova and WGBH. Shown on Nova on 29 March 2005 2 May Riddle of the Human Hobbits, an Equinox Special, a 3 ft 18,000 yr old female was discovered in Indonesia in 2004; the hominids were possibly alive 12,000 years ago, being 1 metre tall, on the Flores islands, east of Indonesia; Australians Mike Morwood, of the University of New England (Australia), and Bert Roberts of the University of Wollongong, with Thomas Sutikna of National Archaeology Research Institute (Indonesia); Leslie C.
==== Infrared spectroscopy ==== The C-H stretching mode gives strong absorptions between 2850 and 2960 cm−1 and weaker bands for the C-C stretching mode absorbs between 800 and 1300 cm−1. The carbon–hydrogen bending modes depend on the nature of the group: methyl groups show bands at 1450 cm−1 and 1375 cm−1, while methylene groups show bands at 1465 cm−1 and 1450 cm−1. Carbon chains with more than four carbon atoms show a weak absorption at around 725 cm−1.
=== Pharmacodynamics === Esmodafinil has about 3-fold lower affinity for the dopamine transporter (DAT) compared to armodafinil or modafinil (Ki = 780 nM, 2,500 nM, and 2,300 nM, respectively). It showed about 2-fold lower potency than armodafinil and about 1.5-fold higher potency than modafinil as a dopamine reuptake inhibitor (DRI) in vitro (IC50Tooltip half-maximal inhibitory concentration = 8,700 nM, 4,000 nM, and 13,000 nM, respectively). Both enantiomers of modafinil preferentially bind to the DAT in an inward facing conformation that is associated with atypical DRI profiles. Esmodafinil was about 1.4- to 1.5-fold more potent than modafinil or armodafinil in substituting for cocaine in rodents. Esmodafinil and armodafinil have been said to have approximately equipotent pharmacological effects but differing pharmacokinetics. Esmodafinil has been researched for the treatment of cocaine addiction. Like armodafinil, esmodafinil attenuates the effects of cocaine by occupying the dopamine transporter. While doing so, esmodafinil increases dopamine levels in the nucleus accumbens to a lesser extent than cocaine. However, the short elimination half-life of esmodafinil has been cited as reason to investigate armodafinil as a cocaine addiction treatment instead.
Sources: en.wikipedia.org
Aminopeptidase regulator of tumour necrosis factor receptor 1 (TNFR1) shedding (ARTS-1) Adipocyte-derived leucine aminopeptidase (A-LAP) Puromycin-insensitive leucyl-specific aminopeptidase (PILS-AP) KIAA0525 In mice, ER aminopeptidase associated with antigen processing (ERAAP)
Christine Helen Foyer (born 3 October 1952) is professor of plant science at the University of Birmingham, Birmingham, UK. She is President Elect of the Association of Applied Biologists, the General Secretary of the Federation of European Societies of Plant Biologists, an elected Board Member of the American Society of Plant Biologists and a Member of the French Academy of Agriculture. She has published and co-authored many papers on related subjects. Foyer's name is included in the "Foyer–Halliwell–Asada" pathway, a cellular process of hydrogen peroxide metabolism in plants and animals and named for the three principal discoverers.
The college's prospectus, published in 1884, offered three diplomas: Christian Scientist (C.S.) for Christian Scientists' Association members; Christian Metaphysician (C.M.) for Eddy's 12-lesson course and three years' practice; and Doctor of Christian Science (D.C.S.) for C.M.s whose "life and character conform to Divine science." In 1886, the Bachelor of Christian Science (C.S.B.) diploma was offered. Students could study metaphysics, science of the scriptures, mental healing and obstetrics, using two textbooks, Science and Health and the Bible. Between 1881 and October 1889, when Eddy closed the college, 4,000 students took the course at $300 per person or married couple, making her a rich woman. Mark Twain wrote sarcastically that she had turned a sawdust mine (possibly Quimby's) into a Klondike.
== Structure and function == Motor nerve fibers transduce signals from the CNS to peripheral neurons of proximal muscle tissue. Motor nerve axon terminals innervate skeletal and smooth muscle, as they are heavily involved in muscle control. Motor nerves tend to be rich in acetylcholine vesicles because the motor nerve, a bundle of motor nerve axons that deliver motor signals and signal for movement and motor control. Calcium vesicles reside in the axon terminals of the motor nerve bundles. The high calcium concentration outside of presynaptic motor nerves increases the size of end-plate potentials (EPPs).
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.